THOUSAND OAKS, Calif., Feb. 21, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has adopted a decision to change the Repatha ® (evolocumab) marketing ...

--Amgen today announced new Repatha ® combined data from the Phase 3 FOURIER and FOURIER Open Label Extension studies and the Phase 2 OCEAN- DOSE study of investigational olpasiran, an siRNA that ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Amgen announced results from a large real-world study showing that treatment with Repatha (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with ...

THOUSAND OAKS, Calif., Dec. 1, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that following priority review of its supplemental Biologics License Application, the U.S. Food and Drug ...

The government’s approval of a new drug to lower cholesterol could mean billions of dollars for Thousand Oaks biotech giant Amgen — and spark a new round of debate over the thousands of dollars it ...

Amgen (AMGN) said new findings from a pre-specified Phase 3 VESALIUS-CV trial analysis showed Repatha (evolocumab) reduced the risk of death by 20% in high-risk adults without a prior heart attack or ...

THOUSAND OAKS, Calif., Amgen today announced the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of a single-dosing option for the monthly administration ...

Federal Circuit invalidated patents on blockbuster Amgen cholesterol drug U.S. Solicitor General says decision was reasonable (Reuters) - The Biden Administration told the U.S. Supreme Court on ...